Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017

Cited by 911 works. doi:10.1016/s0140-6736(17)30565-2

Authors

References